http://zyvox.legalview.com/msn/ 2012-02-23 http://zyvox.legalview.com/msn/trius-therapeutics-initiates-phase-3-program-of-oral-torezolid-phospha/1235325/ 2012-02-23 http://zyvox.legalview.com/msn/trius-therapeutics-initiates-phase-3-program-of-oral-torezolid-phospha/1235324/ 2012-02-23 http://zyvox.legalview.com/msn/a-radical-plan-to-save-antibiotics/1235323/ 2012-02-23 http://zyvox.legalview.com/msn/paratek-to-present-clinical-data-at-the-50th-interscience-conference-o/1235322/ 2012-02-23 http://zyvox.legalview.com/msn/trius-therapeutics-begins-clinical-trials/1235321/ 2012-02-23 http://zyvox.legalview.com/msn/poor-hygiene-a-danger-at-outpatient-surgery-centers/1197321/ 2012-02-23 http://zyvox.legalview.com/msn/study-examines-icu-outbreak-of-staph-aureus-with-resistance-to-methici/1197320/ 2012-02-23 http://zyvox.legalview.com/msn/news-scan-linezolid-resistant-infections-more-salmonella-cases-who-tra/1197319/ 2012-02-23 http://zyvox.legalview.com/msn/is-lrsa-the-new-mrsa/1197318/ 2012-02-23 http://zyvox.legalview.com/msn/trius-therapeutics-obtains-special-protocol-assessment-with-fda-for-ph/1197317/ 2012-02-23 http://zyvox.legalview.com/msn/pfizer-reveals-payments-to-doctors-hospitals/1159290/ 2012-02-23 http://zyvox.legalview.com/msn/drugs-medications-epinephrine-im/1131995/ 2012-02-23 http://zyvox.legalview.com/msn/drugs-medications-darvocet-n-100-oral/1131994/ 2012-02-23 http://zyvox.legalview.com/msn/us-and-european-experts-applaud-creation-of-new-transatlantic-task/1131993/ 2012-02-23 http://zyvox.legalview.com/msn/drug-makers-find-law-a-bitter-pill/1131992/ 2012-02-23 http://zyvox.legalview.com/msn/novexel-commences-comparative-study-of-nxl103-to-oral-linezolid/1131991/ 2012-02-23 http://zyvox.legalview.com/msn/good-things-in-threes-trius-therapeutics-files-for-ipo-to-fund-phase/1131990/ 2012-02-23 http://zyvox.legalview.com/msn/despite-omeros-flop-trius-and-other-biotech-ipo-hopefuls-might-fare/1131989/ 2012-02-23 http://zyvox.legalview.com/msn/unorthodox-approach-to-the-development-of-a-new-antituberculosis/1109611/ 2012-02-23 http://zyvox.legalview.com/msn/trius-announces-positive-results-from-phase-2-clinical-trial-of/1109610/ 2012-02-23 http://zyvox.legalview.com/msn/skin-and-skin-structure-infections-are-the-second-most-common/1109609/ 2012-02-23 http://zyvox.legalview.com/msn/astrazeneca-and-forest-laboratories-to-co-develop-and-commercialise-a/1109608/ 2012-02-23 http://zyvox.legalview.com/msn/staph-germs-harder-than-ever-to-treat-studies-say/1109607/ 2012-02-23 http://zyvox.legalview.com/msn/minnesota-bacterial-resistance-prompts-concern/1109606/ 2012-02-23 http://zyvox.legalview.com/msn/pfizer-profit-dips-2-percent-sales-fall-much-more/1109605/ 2012-02-23 http://zyvox.legalview.com/msn/trius-developer-of-antibiotic-for-deadly-mrsa-bacteria-passes-key/1109604/ 2012-02-23 http://zyvox.legalview.com/msn/trius-looks-to-cut-a-deal-gears-up-for-final-stage-of-trials-with-new/1109603/ 2012-02-23 http://zyvox.legalview.com/msn/fda-panel-theravance-antibiotic-safe-effective/1109602/ 2012-02-23 http://zyvox.legalview.com/msn/rib-x-pharmaceuticals-reports-positive-phase-2-study-results-for/1109601/ 2012-02-23